Results 11 to 20 of about 7,329,727 (241)

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma

Advances in Respiratory Medicine, 2023
Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed ...
Serafeim-Chrysovalantis Kotoulas, Ioanna Tsiouprou, Kalliopi Domvri, Polyxeni Ntontsi, Athanasia Pataka, Konstantinos Porpodis   +5 more
doaj   +4 more sources

Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review [PDF]

Respiratory Research, 2019
Background Guidelines recommend that treatment with a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), i.e.
Sue Langham, Jen Lewis, Nick Pooley, Nina Embleton, Julia Langham, MeiLan K. Han, James D. Chalmers   +6 more
doaj   +7 more sources

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD [PDF]

New England Journal of Medicine, 2018
The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid-LABA or LAMA-LABA), are uncertain.In this randomized trial involving 10,355 patients with COPD, we ...
David A. Lipson, Dave Singh, Fernando J Martinez   +2 more
exaly   +12 more sources

The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice [PDF]

Медицинский совет, 2022
Introduction. About 40% of patients with bronchial asthma on dual therapy with inhaled glucocorticosteroids and long-acting β2-agonists do not achieve asthma control.Aim.
V. V. Naumova, E. K. Beltyukov, V. Ch. Abdullaev, E. V. Shevtseva   +3 more
doaj   +4 more sources

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. [PDF]

ERJ Open Res, 2021
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (100/62.5/25 µg) improved clinical outcomesversusbudesonide ...
Fenwick E, Martin A, Schroeder M, Mealing SJ, Solanke O, Risebrough N, Ismaila AS.   +6 more
europepmc   +5 more sources

Single inhaler triple therapy in COPD – all that glitters is not gold

Monaldi Archives for Chest Disease, 2021
Dear Editor, The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/
Kartik Deshmukh, Arjun Khanna
doaj   +4 more sources

Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review

Expert Review of Respiratory Medicine, 2022
Evidence from non-randomized studies shows benefits for single-inhaler users compared with multiple-inhaler users who receive the same medication. As a result, comparative cost-effectiveness studies are required to inform treatment decisions with an increasing choice of medications and devices for chronic obstructive pulmonary disease (COPD).
Rezwanul Hasan Rana, Khorshed Alam, Syed Afroz Keramat, Jeff Gow   +3 more
openaire   +6 more sources

Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)

BMJ Open Respiratory Research, 2023
Introduction From 2018 single inhaler triple therapy (SITT) became available in France to treat moderate-to-severe chronic obstructive pulmonary disease (COPD).
Gaëtan Deslee, Andrew Maguire, Gabriel Thabut, Caroline Fabry-Vendrand, Nolwenn Poccardi, Caroline Eteve Pitsaer, Adrien Coriat, Charlotte Renaudat, Thomas Pinto   +8 more
doaj   +2 more sources

Triple Therapy for COPD: Historical Perspective and Current Controversies

Barcelona Respiratory Network Reviews, 2023
The use of a combination of three inhaled drugs has recently been established as the first choice for some patients in the algorithm for the treatment of chronic obstructive pulmonary disease. In this review, we aim to give an overview of the development
Jose L. López-Campos
doaj   +2 more sources

Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand. [PDF]

BMJ Open Respir Res
Introduction Single-inhaler triple therapy (SITT) is known to be a cost-effective intervention for chronic obstructive pulmonary disease (COPD) in Western countries, but there is no such evidence for resource-limited countries.
Dilokthornsakul P, Dilokthornsakul P, Chongmelaxme B, Niyompattama A.   +3 more
europepmc   +3 more sources